BIOMARKERS FOR DETERMINING RESPONSIVENESS OF A CANCER TO PI3K INHIBITORS Application EP-3841221-A4 European Patent Office 08 Jun 2022
Antineoplastic combinations with mTOR inhibitor, trastuzumab and/or HKI-272 Grant US-10729672-B2 United States of America 04 Aug 2020
Method for treating gefitinib resistant cancer Grant US-10603314-B2 United States of America 31 Mar 2020
Method for treating gefitinib resistant cancer Grant US-10596162-B2 United States of America 24 Mar 2020